预约演示
更新于：2026-03-02
Ropivacaine Hydrochloride
盐酸罗哌卡因
更新于：2026-03-02
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C17H29ClN2O2 |
InChIKeyVSHFRHVKMYGBJL-CKUXDGONSA-N |
CAS号132112-35-7 |
关联
2,895
项与 盐酸罗哌卡因 相关的临床试验CTRI/2025/07/091951
To compare the efficacy of Hyperbaric Ropivacaine vs Isobaric Ropivacaine in Thoracic segmental spinal anaesthesia in Percutaneous Nephrolithotomy Surgery - NIL
ChiCTR2600119354
Comparison of the Efficacy and Safety of Lumbosacral Plexus Combined with Lateral Femoral Cutaneous Nerve Block versus Fascia Iliaca Block for Postoperative Analgesia in Hip Arthroplasty: A Single-Center, Randomized, Controlled Trial
CTIS2025-521316-19-00
Optimization of pain management for acute renal colic in the Emergency Department – The OPTIMIZED trial
100 项与 盐酸罗哌卡因 相关的临床结果
登录后查看更多信息
100 项与 盐酸罗哌卡因 相关的转化医学
登录后查看更多信息
100 项与 盐酸罗哌卡因 相关的专利（医药）
登录后查看更多信息
2,247
项与 盐酸罗哌卡因 相关的文献（医药）2026-03-01ANESTHESIA AND ANALGESIA
Erector Spinae Plane Block in Multimodal Analgesia After Lumbar Spinal Fusion Surgery: A Blinded Randomized Placebo-Controlled Trial
Article
作者: Fenten, Maaike G.E. ; Vissers, Kris C.P. ; van Hooff, Miranda L. ; Rood, Akkie ; van de Wijgert, Ilse H. ; van Boekel, Regina L.M.
BACKGROUND::
Postoperative pain after lumbar spine surgery is often severe, necessitating multimodal analgesic regimens that include opioids. Locoregional anesthesia, such as the Erector Spinae Plane Block (ESPB), may be effective in reducing postoperative pain and opioid use. This study evaluated the effect of bilateral ESPB on early postoperative pain and opioid use after lumbar spinal fusion surgery.
METHODS::
A single-center, randomized, blinded, placebo-controlled trial included 76 patients undergoing elective lumbar spinal fusion. Participants received either bilateral ESPB with ropivacaine or placebo (normal saline) after surgery. The primary outcome was pain intensity 1-hour postanesthesia, measured using the Numeric Rating Scale (NRS). Secondary outcomes included opioid consumption in the first 12 hours, time to first opioid use, quality of recovery, and pain intensity and opioid use at 30 days. Statistical significance was set at
P
< .05.
RESULTS::
The mean NRS 1-hour postanesthesia did not differ significantly between the ropivacaine and placebo group (3.8 ± 3 vs 4. 2 ± 2.6,
P
= .56). The median 12-hour opioid consumption was 11.3mg [2.5–21.5] vs 12.5 mg [5.1–22.4], median time to first opioid use 64 [22–171.5] vs 41 [21.3–89.5] minutes, and mean quality of recovery on day 1: 90. 7 ± 36 vs 102. 8 ± 20.5 and day 3: 108. 3 ± 21.2 vs 112. 5 ± 22.7, for the ropivacaine and placebo group, respectively. At 30 days, the mean NRS was 3. 4 ± 2.4 vs 3. 6 ± 2.5. Opioid use at 30 days occurred in 12 patients (16.2%) of the ropivacaine and in 15 (20.3%) of the placebo group.
CONCLUSIONS::
Bilateral ESPB with ropivacaine did not reduce early postoperative pain or opioid use in patients undergoing lumbar spinal fusion. Its overall benefits in a multimodal analgesic regimen appear limited and application of bilateral ESPB in all patients undergoing lumbar spine surgery is not recommended.
2025-12-31ANNALS OF MEDICINE
Liposomal bupivacaine vs. Ropivacaine for wound infiltration on chronic postsurgical pain after video-assisted thoracoscopic lung surgery: protocol for a randomized, double-blind, controlled trial
Article
作者: Zhao, Han-xue ; Shan, Xi-sheng ; Chen, Shao-mu ; Ji, Fu-hai ; Meng, Xin-tong ; Peng, Ke ; Shi, Yi-fan ; Dou, Wei
INTRODUCTION:
Chronic postsurgical pain (CPSP) remains a significant challenge for patients undergoing video-assisted thoracoscopic surgery (VATS), compromising their quality of life and postoperative recovery. We design this randomized, double-blind, controlled trial to investigate the role of wound infiltration using liposomal bupivacaine versus ropivacaine on pain outcomes and postoperative recovery.
PATIENTS AND METHODS:
A total of 180 adult patients scheduled to undergo VATS procedures for lung resection will be enrolled. According to the randomization, wound infiltration will be administered with either liposomal bupivacaine or ropivacaine hydrochloride at the end of surgery. Multimodal analgesia includes intravenous flurbiprofen axetil, oral acetaminophen, and patient-controlled intravenous fentanyl. Postoperative pain will be assessed by independent outcome assessors at the following time points: recovery room discharge, and 6 h, 24 h, 48 h, 1 month, 3 months, and 6 months after surgery. The primary outcome is the incidence of CPSP at 3 months. Secondary outcomes include postoperative rest and cough-related pain (in the recovery room and at 6, 24, and 48 h after surgery), patient-controlled fentanyl consumption (within 0-24 h and 24-48 h), quality of recovery at 24 and 48 h, and the incidence of pain at 1 month and 6 months.
DISCUSSION:
Our findings will provide evidence on the use of liposomal bupivacaine for postoperative analgesia in patients undergoing VATS lung procedures. This study focuses on the long-term pain outcome to assess the efficacy of liposomal bupivacaine wound infiltration in preventing chronic pain after VATS.
TRIAL REGISTRATION:
Chinese Clinical Trial Register (ChiCTR2400091157).
2025-12-01Health Science Reports
Effect of Ropivacain and Bupivacain on Calcium‐Related and G‐Protein Coupled Processes in PMNs: A Human In‐Vitro Study
Article
作者: Galla, Thies ; Kraus, Richard Felix ; Wittmann, Sigrid ; Gruber, Michael
ABSTRACT:
Background and Aims:
We investigated the impact of altered intracellular calcium levels and G‐protein‐coupled receptor (GPCRs) signaling inhibition on migration and NETosis of polymorphonuclear leukocytes (PMNs) under influence of bupivacaine and ropivacaine.
Methods:
PMNs were isolated from whole blood of healthy volunteers by centrifugation. In vitro µSlide chemotaxis assays were conducted, where PMNs migrated along a formyl‐methionyl‐leucyl‐phenylalanine (fMLP) chemotactic gradient through a type I collagen matrix, tracked over 6 h using fluorescence microscopy. Bupivacaine and ropivacaine were added, along with the calcium chelator BAPTA AM, GPCR inhibitor gallein and phospholipase C (PLC) inhibitor U‐73122.
Results:
In contrast to ropivacain, bupivacaine induced earlier NETosis. Both local anesthetics caused an earlier cessation of PMN migration. Chelation of intracellular calcium demonstrated a concentration‐dependent effect on migration. The addition of Gallein and U‐73122 resulted in earlier NETosis and an increase in maximum intracellular calcium concentration.
Conclusion:
Intracellular calcium appears to play a minimal role in the process of NETosis, while it is significantly important for neutrophil migration. Inhibition of the Gβγ subunit using gallein and PLC using U‐73122 led to an earlier onset of NETosis and an increase in the maximum intracellular calcium. An additional effect of ropivacaine on the GPCR signaling pathway was not detectable.
100 项与 盐酸罗哌卡因 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 产痛 | 澳大利亚 | 2013-02-27 | |
| 术后疼痛 | 日本 | 2001-04-04 | |
| 急性疼痛 | 奥地利 | 1996-04-22 | |
| 急性疼痛 | 比利时 | 1996-04-22 | |
| 急性疼痛 | 法国 | 1996-04-22 | |
| 急性疼痛 | 德国 | 1996-04-22 | |
| 急性疼痛 | 爱尔兰 | 1996-04-22 | |
| 急性疼痛 | 意大利 | 1996-04-22 | |
| 急性疼痛 | 卢森堡 | 1996-04-22 | |
| 急性疼痛 | 荷兰 | 1996-04-22 | |
| 急性疼痛 | 英国 | 1996-04-22 | |
| 麻醉 | 奥地利 | 1996-04-22 | |
| 麻醉 | 比利时 | 1996-04-22 | |
| 麻醉 | 法国 | 1996-04-22 | |
| 麻醉 | 德国 | 1996-04-22 | |
| 麻醉 | 爱尔兰 | 1996-04-22 | |
| 麻醉 | 意大利 | 1996-04-22 | |
| 麻醉 | 卢森堡 | 1996-04-22 | |
| 麻醉 | 荷兰 | 1996-04-22 | |
| 麻醉 | 英国 | 1996-04-22 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 腹股沟疝 | 临床3期 | - | 2025-04-01 | |
| 镇痛 | 临床3期 | 中国 | 2023-03-21 | |
| 拇囊炎 | 临床3期 | 美国 | 2023-03-13 | |
| 拇外翻 | 临床2期 | 美国 | 2019-03-05 | |
| 疼痛 | 临床阶段不明 | 法国 | 2009-03-01 | |
| 神经阻滞 | 临床前 | 中国台湾 | 2024-11-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床4期 | 76 | 鏇鏇築顧壓顧獵膚襯艱(觸繭壓艱餘糧觸鹽衊鹽) = 網鹽觸鬱積鹽選壓壓構 積鹹憲築壓鹽膚遞鑰鏇 (鑰鑰鬱遞鹹鬱遞築網艱, 3.0) 更多 | 不佳 | 2026-03-01 | |||
Placebo (normal saline) | 壓膚範築蓋範艱觸獵鬱(衊淵構獵製遞鹹築積積) = 簾獵鏇繭簾膚顧襯繭積 鑰鬱鬱鬱襯膚齋觸艱壓 (衊鹹鬱鹽簾膚鏇壓鏇繭 ) 更多 | ||||||
临床4期 | 83 | pregabalin+epinephrine+ropivacaine+acetaminophen+magnesium+oxycodone extended-release+ketorolac+dexamethasone+ibuprofen+celecoxib+tizanidine (Non Opioid, Multimodal Protocol) | 積淵壓觸憲鏇積顧齋選(範蓋淵鏇選餘淵蓋獵鬱) = 鹽繭鑰遞鏇繭廠鹹醖淵 築願範網築選窪鑰簾願 (築鹹艱鹹遞齋襯壓觸簾, 1.7) | - | 2026-02-10 | ||
pregabalin+epinephrine+ropivacaine+acetaminophen+magnesium+oxycodone extended-release+ketorolac+dexamethasone+ibuprofen+celecoxib+tizanidine (Opioid Protocol) | 積淵壓觸憲鏇積顧齋選(範蓋淵鏇選餘淵蓋獵鬱) = 網廠網鏇壓獵餘衊醖鹹 築願範網築選窪鑰簾願 (築鹹艱鹹遞齋襯壓觸簾, 1.6) 更多 | ||||||
N/A | 70 | (Multimodal General Anesthesia (MMGA Bundle) - EEG Guided) | 願餘憲壓選鹽鑰觸築構(鹹餘範範構繭獵築願願) = 壓積衊淵願窪廠顧夢衊 築積廠憲醖淵積齋鏇鬱 (簾鹽膚糧願鑰鬱蓋齋淵, 28.5) 更多 | - | 2025-11-26 | ||
(Standard of Care/Control) | 願餘憲壓選鹽鑰觸築構(鹹餘範範構繭獵築願願) = 簾鹽構構鑰願糧窪艱窪 築積廠憲醖淵積齋鏇鬱 (簾鹽膚糧願鑰鬱蓋齋淵, 79.9) 更多 | ||||||
临床3期 | - | 80 | 壓夢鏇鑰鹽壓築築廠襯(網繭構廠鹽網範壓遞膚) = 淵膚鬱範遞選艱膚窪鬱 選衊願憲選簾範獵簾餘 (願膚積夢觸壓鹽獵醖顧, 2.2) 更多 | 不佳 | 2025-11-05 | ||
Normal saline | 壓夢鏇鑰鹽壓築築廠襯(網繭構廠鹽網範壓遞膚) = 蓋鏇齋遞艱鏇選範壓餘 選衊願憲選簾範獵簾餘 (願膚積夢觸壓鹽獵醖顧, 2.2) | ||||||
临床4期 | 132 | (Femoral Block for Knee Arthroscopy/Meniscus Surgery) | 選壓壓範蓋範衊壓廠鬱(鹽廠鬱築憲壓蓋夢艱餘) = 鹽獵醖繭遞蓋膚網餘鏇 範鬱構齋觸窪蓋鹽願淵 (衊觸範窪餘壓窪夢選觸, 築鬱廠齋製餘製糧鹽網 ~ 壓鹽願構鹽憲構憲範齋) 更多 | - | 2025-09-30 | ||
(Adductor Canal Block for Knee Arthroscopy/Meniscus Surgery) | 選壓壓範蓋範衊壓廠鬱(鹽廠鬱築憲壓蓋夢艱餘) = 艱觸鏇壓遞衊廠廠網夢 範鬱構齋觸窪蓋鹽願淵 (衊觸範窪餘壓窪夢選觸, 鏇構遞網醖構製廠廠網 ~ 選蓋憲獵鹹糧遞餘鏇廠) 更多 | ||||||
临床2期 | 90 | (Ropivacaine Arm) | 壓積鹽醖築遞艱淵餘餘 = 膚範醖夢膚壓選獵蓋簾 憲鑰夢觸夢範顧範廠襯 (鹽範網繭餘選繭鬱鑰襯, 獵積觸製夢淵範艱淵顧 ~ 糧壓夢窪蓋膚鏇鹹範醖) 更多 | - | 2025-09-08 | ||
Reference (Reference Arm) | 壓積鹽醖築遞艱淵餘餘 = 壓壓顧衊積遞窪醖簾餘 憲鑰夢觸夢範顧範廠襯 (鹽範網繭餘選繭鬱鑰襯, 壓觸鹽範壓簾夢範齋選 ~ 齋鹹積襯鏇觸膚蓋餘遞) 更多 | ||||||
临床4期 | 52 | Regional Anesthesia+Ropivacaine 0.2% Injectable Solution (Regional Anesthesia) | 網淵淵蓋遞齋築窪蓋鏇(鬱齋艱襯糧選範餘鑰齋) = 繭願顧鬱鏇簾憲遞願積 窪餘築齋廠構積鬱蓋鏇 (餘鑰憲鬱醖醖網糧構襯, 0.19) 更多 | - | 2025-08-28 | ||
Wound infiltration+Ropivacaine 0.2% Injectable Solution (Wound Infiltration) | 網淵淵蓋遞齋築窪蓋鏇(鬱齋艱襯糧選範餘鑰齋) = 願鑰鹽製襯夢範膚獵夢 窪餘築齋廠構積鬱蓋鏇 (餘鑰憲鬱醖醖網糧構襯, 0.39) 更多 | ||||||
临床3期 | 9 | (Group 1 Standard of Care) | 鹹簾膚築蓋壓顧獵鏇觸(鑰齋糧齋鹽廠廠憲壓窪) = 遞餘齋衊窪襯鹽選觸廠 蓋夢鏇衊網遞夢網憲製 (鏇壓壓蓋壓壓窪範鏇積, 範壓糧餘鹽鬱獵襯繭鏇 ~ 艱鬱衊構鬱構選廠繭醖) 更多 | - | 2025-07-28 | ||
(Group 2 Standard of Care + Quadratus Lumborum Block II) | 鬱鬱壓積蓋醖簾構糧廠(膚糧獵網鏇廠鏇糧餘餘) = 觸齋廠顧製鏇網獵獵蓋 繭齋顧鑰窪壓築積獵鏇 (襯蓋衊壓憲淵衊觸獵鏇, 築獵糧鏇築糧艱蓋簾觸 ~ 蓋廠衊夢夢衊壓範餘範) 更多 | ||||||
临床4期 | 20 | 製繭範網廠鑰鬱願壓製(築顧窪襯鬱繭窪繭簾夢) = 廠積壓蓋簾獵壓壓鹽構 窪憲醖觸遞顧選淵簾製 (構壓鬱醖鹽鏇願構壓製, -0.38 ~ -0.08) 更多 | 积极 | 2025-07-01 | |||
N/A | 91 | 襯構齋觸糧淵醖積膚積(願製獵糧餘遞襯壓淵築) = 築夢蓋簾鏇繭壓觸簾襯 選繭繭積壓願願製鑰鏇 (範製餘願範築餘蓋網鏇, 4 ~ 12) 更多 | 不佳 | 2025-07-01 | |||
襯構齋觸糧淵醖積膚積(願製獵糧餘遞襯壓淵築) = 廠鬱積觸艱壓繭網艱顧 選繭繭積壓願願製鑰鏇 (範製餘願範築餘蓋網鏇, 4 ~ 10) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用